Rationale and Objectives: F18-fluorodeoxyglucose (FDG)-positron emission tomography (PET) studies have clinical value in suspected recurrent or metastatic colorectal cancer cases. Because this modality is not accessible for many patients, a camera-based FDG (CB-FDG) coincidence imaging was suggested as an alternative. Although inferior in resolution to a dedicated PET system, it can make FDG studies available to more patients. We assessed the clinical value of CB-FDG in patients with recurrent colorectal cancer.
T he use of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) is now recognized as an accurate diagnostic modality for the evaluation of recurrent colorectal carcinoma (CRC). By providing more accurate staging, this modality can improve patient selection before surgery and have an impact on the optimal use of medical treatment, thus affecting patient outcome. FDG-PET for the detection of a viable tumorous tissue is based on an increased glucose uptake and on the metabolism of cancer cells. 1, 2 Previous publications have reported a high sensitivity and specificity of FDG-PET in the detection of a variety of human malignancies, including recurrent or metastatic CRC. [3] [4] [5] [6] [7] Most data on FDG in clinical oncology are based on the use of dedicated PET systems, which are beyond reach for many patients with cancer. In recent years, gamma cameras, which are used in the routine practice of general nuclear medicine, have been upgraded to detect radiopharmaceuticals labeled with positron emitters, mainly FDG. 8, 9 Although inferior to dedicated PET systems, camera-based FDG coincidence imaging, mainly with iterative reconstruction algorithms (CB-FDG), allows for a significantly larger number of patients to benefit from an FDG assessment. We have recently evaluated the role of CB-FDG in patients with CRC, and our results showed this modality to have good diagnostic accuracy. Specifically, CB-FDG was found to accurately detect the tumor lesions in patients with an unexplained rising carcinoembryonic antigen (CEA) level, to detect extraabdominal disease, and in restaging. 10, 11 The purpose of the current study was to assess the clinical impact of CB-FDG in patients with recurrent and/or metastatic CRC. The clinical staging and the appropriate treatment approach were twice determined by an oncologist and by an oncologic surgeon; the first decision was based on the medical records before the FDG assessment and the second took the FDG results into consideration in the decision-making analysis.
MATERIALS AND METHODS

Patient Population
This study is a retrospective one. Between February 1999 and August 2001, CB-FDG studies were performed on 83 patients with CRC who had suspected or known recurrent or metastatic disease. There were 42 females and 41 males with an age range of 25-85 years (mean 64 Ϯ 13 years). The indications for dual headed camera-FDG were an unexplained rising CEA level (n ϭ 31) and restaging of suspected recurrence or metastatic disease on computerized tomography (CT), ultrasonography (US), or colonoscopy (n ϭ 52).
Coincidence Imaging
The patients fasted for at least 4 hours before the intravenous injection of 370 -700 MBq (10 -19 mCi) of 18 F-FDG. Imaging started approximately 60 minutes after the injection. Coincidence studies were performed by using a dual-head gamma camera with coincidence imaging capacity and equipped with 2-5/8-inch (16-mm) thick NaI(Tl) crystals (Millenium VG, GE Medical System, Milwaukee, WI) (n ϭ 72 studies) or by using a dual-head gamma camera with 1-inch (25.4-mm) thick NaI(Tl) crystals (Discovery VH, GE Medical System) (n ϭ11 studies).
Emission data acquisition for each of the systems lasted 30 minutes per field of view, corresponding to 10 rotations of the gantry. For the transmission part, the full field of view consisting of 40 slices was completed in 10 minutes. An iterative reconstruction algorithm was used for the emission data. The transmission was reconstructed using a filtered backprojection technique. The proprietary algorithm, "coincidence list ordered set expectation maximization" (COSEM), which is a 3-dimensional algorithm that directly processes the coincidence list mode (CLIST), was used for the reconstruction of the CLIST. 8 The transmission data added to the emission data were used for attenuation correction of the emission images as well as to create single photon emission computed tomography-CT (functional-anatomic) fused images. 9, 12 Scintigraphic findings were interpreted separately in a consensus reading by 2 readers (EE-S and HL) who were blinded to clinical data as well as to findings on other imaging modalities.
Lesion-Based Analysis
For analyzing the results, FDG findings were categorized as true-positive for tumor (TP), true-negative (TN), false-positive (FP), and false-negative (FN) using the histopathologic results, the correlations with contemporaneous radiographic assessment (including, CT, US, and magnetic resonance imaging [MRI] studies) and/or clinical and imaging follow up of at least 12 months (mean 17.4 Ϯ 5.6 months; range, 12-30 months) as the standard of reference.
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Assessment of Clinical Impact
To assess the clinical impact of CB-FDG imaging in patients with recurrent CRC, an oncologist specializing in gastrointestinal tract malignancies (AF) and an oncologic surgeon (MG) independently filled out a questionnaire on the disease stage and the suggested treatment approach based on the medical records of the patient before the CB-FDG study. They repeated this process once more after obtaining the CB-FDG study results.
RESULTS
CB-FDG studies detected 117 lesions, of which 101 were TP, 9 were TN, 5 were FN, and 2 were FP, resulting in a sensitivity of 95% and a specificity of 81%. The final diagnosis of the lesions was based on histology obtained at surgery or by biopsy (n ϭ 38), correlation with contemporaneous imaging modalities and/or radiologic follow up (n ϭ 50), and on clinical follow up (n ϭ 19). The latter applies to patients with suggested nodal or peritoneal metastatic spread on CB-FDG, who showed a rapid clinical deterioration. Correlation with CT was available for 82 lesions: 57 were TP, 11 were TN, 8 were FN, and 6 were FP, resulting in a sensitivity of 88% and a specificity of 64%.
Staging of Disease
Before the FDG assessment, 57 patients had known or suspected sites of tumor, and recurrence or metastatic spread was clinically suspected but were not localized in 26 patients. In 21 of these 26 patients (81%), CB-FDG revealed the tumor sites. The tumor sites detected solely by FDG included extrahepatic abdominal spread (n ϭ 13), hepatic lesions (n ϭ 6), recurrence at the site of the previous surgery (n ϭ 5), and extraabdominal metastases (n ϭ 3). Of the 57 patients who had evidence of disease before CB-FDG, disease distribution was changed based on the added FDG data in 30 of them (53%). Figure 1 displays the specific disease distribution 
Treatment Approach
Based on the addition of the FDG results, the treatment approach suggested by the oncologist was altered in 54% of the patients, whereas the treatment approach of the surgeon was altered in 28% of the patients. In 16 of 43 patients (37%) in whom surgery was considered before FDG, additional disease sites were detected by the CB-FDG assessment and surgery was no longer the treatment of choice. In contrast, in 8 of 40 (20%) remaining patients, the lesions detected by FDG raised the possibility of surgery with a curative intent. Table 1 summarizes the changes in patient management suggested by the oncologist and by the surgeon based on the findings of the CB-DHC imaging (Figs. 2 and 3) 
DISCUSSION
Accuracy in the determination of disease extent and the selection of an appropriate treatment approach are major factors in the outcome of patients with recurrent CRC. If recurrence or metastatic spread is suspected, the prognosis of the patients depends on the potential to perform surgery with a curative intent and to remove all the active tumoral tissue. 13 Unnecessary operations, on the other hand, should be avoided in patients with documented widespread disease. 12 The conventional imaging modalities routinely used in restaging of CRC include CT, US, 
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and colonoscopy. The limitations of the latter techniques have been pointed out by various studies.
14 A whole-body PET-FDG has proved effective for tumor detection of recurrences in patients with different tumor types, including CRC. Its substantial impact on the management of patients with CRC indicates that it is a more sensitive test than conventional imaging in detecting tumorous lesions. 12, 15 The number of available PET systems, however, is still limited and therefore beyond the reach of many patients who might benefit from an FDG assessment. The conventional multihead gamma cameras used in the routine practice of nuclear medicine for the detection of single photon emitters have been recently modified to also function for the detection of positron emitters, thereby increasing the potential number of patients who can be afforded the opportunity to undergo an FDG study. Although tumor detection by a dedicated PET system is superior to that obtained by the camera-based technique, the results of studies that have used the CB-FDG technique in various types of malignancies show promise for its use as an alternative when a dedicated PET device is not available.
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The current study investigated the clinical impact of CB-FDG on the staging and management approach in patients with recurrent CRC. The clinical impact of the FDG data was considered by 2 clinicians, an oncologic specialist of the gastrointestinal tract and by an oncologic surgeon. FDG findings altered the disease stage in 57% of the study patients by upstaging it in 42% and downstaging it in 15%. FDG localized the tumor sites in 21 of 26 patients (81%) with suspected clinical recurrence and a negative conventional imaging workup. The suggested appropriate clinical approach provided by the oncologist was altered in 54% of the patients, and in 28% of the patients, the surgeon altered the decision on the operability of the disease. In 8 of 40 patients in whom the disease was considered inoperable, FDG detected disease sites that were appropriate for a surgical procedure with a curative intent. In 16 of 43 (37%) in whom surgery was considered before FDG, unsuspected disease sites were detected on the FDG assessment and surgery was no longer an option.
A recent report by Joubin et al. investigated the clinical impact of FDG assessment in patients with CRC from the referring physician's point of view. They reported alteration of the clinical staging in 42% of the patients and a change in the clinical management was suggested in 60% of the patients.
14 In another study, Ak et al. reported a change in clinical management based on FDG results in 40% (16 of 40) of patients with CRC. 16 A dedicated PET system had been used in both of studies. Studies aimed to compare tumor detection by CB-FDG, and dedicated PET have reported that many of the lesions depicted by PET are also detected using the coincidence technique. However, images obtained by CB-FDG are prone to degradation by the scatter and random coincidence events, and the sensitivity of CB-FDG is lower in the case of small lesions, particularly when located in the abdomen. 17, 18 The sensitivity calculated for CB-FDG in the current study is surprisingly high. A possible explanation might be the high incidence of true-positive tumor sites as a result of a preselection of patients. At the time of the study, FDG has been just introduced in the clinical practice of colorectal cancer in our institute, and only patients with a high clinical or imaging suspicion of recurrence were referred for an FDG assessment.
In conclusion, our results indicate that a camera-based FDG assessment is valuable for restaging and selection of the appropriate treatment approach in patients with CRC and known or suspected recurrence.
